Evogene Ltd. has announced its financial results for the third quarter and first nine months of 2026, emphasizing its ongoing advancements in drug discovery and agricultural chemicals. This update is significant as it reflects the company’s strategic focus on leveraging artificial intelligence to develop innovative products in a competitive industry.
Founded in Rehovot, Israel, Evogene Ltd. operates under the SIC classification of 2870, which pertains to Agricultural Chemicals. The company trades on the Nasdaq under the ticker symbol EVGN. Evogene specializes in computational chemistry, utilizing proprietary AI-driven technologies to design and develop novel small molecules for pharmaceutical and agricultural applications.
In its recent filing, Evogene detailed its financial performance for the quarter ending September 30, 2026. The report highlighted a net loss of approximately $2.9 million for the third quarter, contrasting with a net income of about $5.2 million during the same period in 2025. This shift is attributed to lower revenues and significant income recognized in the previous year from a transaction with ICL.
Ofer Haviv, President and CEO of Evogene, stated, "During the third quarter, we continued to advance our strategy of leveraging our proprietary AI-driven discovery platform, ChemPass AI™, to develop innovative small-molecule-based products with significant commercial potential." The company is particularly focused on two internal development programs: one targeting acute graft-versus-host disease (aGVHD) and the other through its subsidiary AgPlenus, which is working on fungicides to combat Septoria tritici blotch.
As of September 30, 2026, Evogene reported consolidated cash and equivalents of approximately $9.2 million, with cash usage during the third quarter amounting to about $2.4 million. Revenues for the nine months of 2026 totaled approximately $0.8 million, down from $3.2 million in the same period of 2025, primarily due to a decline in revenue from its subsidiary Casterra.
Research and development expenses for the nine months of 2026 were approximately $4.5 million, slightly lower than the previous year. The company is also managing its sales and marketing expenses, which decreased to around $0.9 million for the nine months compared to $1.1 million in 2025.
Evogene's focus on advancing its internal drug discovery program and the development of new agricultural solutions reflects its commitment to addressing significant challenges in the agricultural chemicals sector. The company aims to create proprietary assets that offer long-term value to shareholders.
The filing does not specify what steps Evogene will take next, but it indicates a continuing commitment to innovation and strategic partnerships in the agricultural and pharmaceutical industries.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










